EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)

Abstract

Therapy of CRPC is one of the most difficult problems in oncourology. Until now the optimal consequence of use of drugs in CRPC is not determined.Study objective: evaluation of effectiveness of sequential therapeutic schemes in progression of m-CRPC: cytotoxic (Docetaxel) or second-line hormonal therapy (Abiraterone) after previous treatment by an analogue of prolonged action somatostatin (Octreotide-depo) and without it.Materials and methods: the study design included 4 groups of patients (170 subjects). The first two groups included patients who received initial therapy by Octreotide-Depo 30 mg before chemotherapy and second line hormone therapy, compared to two groups of primary chemical and hormone therapy indicated after progression of m-CRPC.Results: the number of patients in whom the reduction of PSA concentration, process stabilization, tolerability profile were analogous in groups receiving Docetaxel as the first-line therapy and in the group after administration of Octreotide-depo. Analogous data were registered in groups who administered Abiraterone.Conclusion: the analysis of the therapeutic results didn’t demonstrate any significant differences in groups that received Docetaxel or Abiraterone as the second-line therapy after administration of Octreotide-Depo with groups of patients with received first-line cytotoxic or hormone therapy, which means lack of resistance after application of the prolonged action somatropin analogue to subsequent schemes of anti-tumour therapy, which allows delaying the dates of the second line chemical or hormonal therapy of CRPC.

Keywords

• castration refractory prostate cancer
• somatostatin analogues
• androgenous deprivation therapy
• abiraterone
• docetaxel